Whittier Trust Co. raised its holdings in shares of Celgene Co. (NASDAQ:CELG) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 115,315 shares of the biopharmaceutical company’s stock after buying an additional 1,102 shares during the period. Whittier Trust Co.’s holdings in Celgene were worth $16,815,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Arcadia Investment Management Corp MI boosted its position in shares of Celgene by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the last quarter. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares during the period. Motco increased its stake in Celgene by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 159 shares during the period. Balentine LLC increased its stake in Celgene by 83.5% in the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 481 shares during the period. Finally, Acropolis Investment Management LLC purchased a new position in Celgene in the 2nd quarter worth about $144,000. Institutional investors and hedge funds own 79.74% of the company’s stock.
CELG has been the topic of a number of research reports. BMO Capital Markets raised their target price on shares of Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, November 17th. Oppenheimer restated a “buy” rating and issued a $170.00 price target on shares of Celgene in a report on Friday, October 20th. Vetr upgraded shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price for the company in a research note on Monday, October 23rd. Cann reiterated a “buy” rating on shares of Celgene in a research note on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the stock. Celgene presently has an average rating of “Buy” and a consensus price target of $131.18.
Shares of Celgene Co. (NASDAQ:CELG) traded up $1.42 during midday trading on Friday, hitting $106.00. The company had a trading volume of 8,748,000 shares, compared to its average volume of 6,330,000. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a PEG ratio of 0.67 and a beta of 1.77.
Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. research analysts expect that Celgene Co. will post 6.69 EPS for the current year.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.